B-intervention	0	11	Pamidronate
O	12	14	in
O	15	18	the
O	19	29	prevention
O	30	32	of
B-condition	33	45	chemotherapy
I-condition	45	46	-
I-condition	46	53	induced
I-condition	54	58	bone
I-condition	59	63	loss
O	64	66	in
O	67	80	premenopausal
O	81	86	women
O	87	91	with
O	92	98	breast
O	99	105	cancer
O	105	106	:
O	107	108	a
O	109	119	randomized
O	120	130	controlled
O	131	136	trial
O	136	137	.

O	138	147	Mortality
O	148	152	from
O	153	159	breast
O	160	166	cancer
O	167	170	has
O	171	180	decreased
O	181	183	in
O	184	189	large
O	190	194	part
O	195	202	because
O	203	205	of
O	206	214	adjuvant
O	215	227	chemotherapy
O	227	228	.

O	229	237	Sequelae
O	238	240	of
O	241	248	therapy
O	249	256	include
O	257	264	ovarian
O	265	272	failure
O	273	276	and
O	277	281	bone
O	282	286	loss
O	286	287	,
O	288	292	loss
O	293	297	that
O	298	303	would
O	304	312	increase
O	313	318	these
O	319	327	patients
O	327	328	'
O	329	333	risk
O	334	336	of
O	337	345	fracture
O	346	350	with
O	351	356	aging
O	356	357	.

O	358	360	In
O	361	365	this
O	366	371	study
O	371	372	,
O	373	375	we
O	376	384	assessed
O	385	388	the
O	389	397	efficacy
O	398	400	of
O	401	412	pamidronate
O	413	415	in
O	416	426	preventing
O	427	431	such
O	432	436	loss
O	436	437	.

O	438	441	The
O	442	447	study
O	448	451	was
O	452	453	a
O	454	455	1
O	455	456	-
O	456	458	yr
O	459	469	randomized
O	469	470	,
O	471	477	double
O	477	478	-
O	478	483	blind
O	483	484	,
O	485	492	placebo
O	492	493	-
O	493	503	controlled
O	504	509	trial
O	510	519	comparing
O	520	531	pamidronate
O	532	534	60
O	535	537	mg
O	538	540	iv
O	541	546	every
O	547	548	3
O	549	555	months
O	556	560	with
B-control	561	568	placebo
O	569	571	in
B-total-participants	572	574	40
B-eligibility	575	588	premenopausal
I-eligibility	589	594	women
I-eligibility	595	599	with
I-eligibility	600	605	newly
I-eligibility	606	615	diagnosed
I-eligibility	616	622	breast
I-eligibility	623	629	cancer
O	629	630	.

O	631	635	Bone
O	636	643	mineral
O	644	651	density
O	652	653	(
O	653	656	BMD
O	656	657	)
O	658	660	of
O	661	664	the
O	665	670	spine
O	671	674	and
O	675	678	hip
O	679	682	and
O	683	693	remodeling
O	694	701	markers
O	702	706	were
O	707	716	monitored
O	717	721	over
O	722	723	1
O	724	726	yr
O	726	727	.

O	728	732	Over
O	733	737	half
O	738	740	of
O	741	744	the
O	745	753	subjects
O	754	760	became
O	761	772	amenorrheic
O	772	773	,
O	774	777	and
O	778	783	those
O	784	787	who
O	788	791	did
O	792	796	were
O	797	798	4
O	799	801	yr
O	802	807	older
O	808	812	than
O	813	818	those
O	819	822	who
O	823	826	did
O	827	830	not
O	831	832	(
O	832	833	P
O	834	835	=
O	836	837	0
O	837	838	.
O	838	840	02
O	840	841	)
O	841	842	.

O	843	846	The
O	847	851	mean
O	852	862	difference
O	863	865	in
B-outcome	866	873	percent
I-outcome	874	880	change
I-outcome	881	883	in
I-outcome	884	887	BMD
I-outcome	888	890	at
I-outcome	891	893	12
I-outcome	894	900	months
O	901	908	between
O	909	912	the
O	913	916	two
O	917	926	treatment
O	927	933	groups
O	934	937	was
O	938	939	5
O	939	940	.
O	940	941	1
O	941	942	%
B-outcome	943	945	at
I-outcome	946	949	the
I-outcome	950	956	lumbar
I-outcome	957	962	spine
O	963	964	(
O	964	965	P
O	966	967	=
O	968	969	0
O	969	970	.
O	970	973	002
O	973	974	)
O	975	977	in
O	978	981	the
O	982	989	overall
O	990	995	study
O	996	1001	group
O	1002	1005	and
O	1006	1007	5
O	1007	1008	%
B-outcome	1009	1011	at
I-outcome	1012	1015	the
I-outcome	1016	1022	lumbar
I-outcome	1023	1028	spine
O	1029	1032	and
O	1033	1034	5
O	1034	1035	.
O	1035	1036	2
O	1036	1037	%
B-outcome	1038	1040	at
I-outcome	1041	1044	the
I-outcome	1045	1050	total
I-outcome	1051	1054	hip
O	1055	1057	in
O	1058	1061	the
O	1062	1073	amenorrheic
O	1074	1082	subgroup
O	1083	1084	(
O	1084	1085	P
O	1086	1087	<
O	1088	1089	0
O	1089	1090	.
O	1090	1092	03
O	1092	1093	)
O	1093	1094	.

B-outcome	1095	1106	Biochemical
I-outcome	1107	1114	markers
I-outcome	1115	1117	of
I-outcome	1118	1122	bone
I-outcome	1123	1133	remodeling
O	1134	1137	did
O	1138	1141	not
O	1142	1148	differ
O	1149	1156	between
O	1157	1160	the
O	1161	1164	two
O	1165	1174	treatment
O	1175	1181	groups
O	1181	1182	,
O	1183	1186	and
O	1187	1196	treatment
O	1197	1200	was
O	1201	1205	well
O	1206	1215	tolerated
O	1215	1216	.

O	1217	1229	Chemotherapy
O	1229	1230	-
O	1230	1237	induced
O	1238	1248	amenorrhea
O	1249	1251	is
O	1252	1258	common
O	1259	1263	with
O	1264	1271	ensuing
O	1272	1276	bone
O	1277	1281	loss
O	1282	1284	at
O	1285	1288	the
O	1289	1294	spine
O	1295	1298	and
O	1299	1302	hip
O	1302	1303	.

O	1304	1315	Pamidronate
O	1316	1325	prevented
O	1326	1330	bone
O	1331	1335	loss
O	1336	1338	at
O	1339	1342	the
O	1343	1348	spine
O	1349	1352	and
O	1353	1356	hip
O	1357	1360	and
O	1361	1364	was
O	1365	1369	well
O	1370	1379	tolerated
O	1379	1380	.
